These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25341748)

  • 21. Clinicopathological features of 70 desmoid-type fibromatoses confirmed by β-catenin immunohistochemical staining and CTNNB1 mutation analysis.
    An J; Woo HY; Lee Y; Kim HS; Jeong J; Kim SK
    PLoS One; 2021; 16(4):e0250619. PubMed ID: 33914771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does the Addition of Mutations of CTNNB1 S45F to Clinical Factors Allow Prediction of Local Recurrence in Patients With a Desmoid Tumor? A Local Recurrence Risk Model.
    Pinto FFE; Mello CAL; Nakagawa SA; Chung WT; Torrezan GT; Barros BDF; Cunha IW; Calsavara VF; Carraro DM; Lopes A
    Clin Orthop Relat Res; 2023 Oct; 481(10):1978-1989. PubMed ID: 37104792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Local recurrence after surgery for primary extra-abdominal desmoid-type fibromatosis.
    van Broekhoven DL; Verhoef C; Elias SG; Witkamp AJ; van Gorp JM; van Geel BA; Wijrdeman HK; van Dalen T
    Br J Surg; 2013 Aug; 100(9):1214-9. PubMed ID: 23804156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. β-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis.
    Huss S; Nehles J; Binot E; Wardelmann E; Mittler J; Kleine MA; Künstlinger H; Hartmann W; Hohenberger P; Merkelbach-Bruse S; Buettner R; Schildhaus HU
    Histopathology; 2013 Jan; 62(2):294-304. PubMed ID: 23020601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.
    Sakai T; Nishida Y; Hamada S; Koike H; Ikuta K; Ota T; Ishiguro N
    Diagn Pathol; 2017 Aug; 12(1):66. PubMed ID: 28851389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinicopathological and molecular genetic features of neuromuscular choristoma-associated desmoid type fibromatosis].
    Dong RF; Guo W; Li N; Wang ZY; Sun XQ; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2024 Jul; 53(7):685-690. PubMed ID: 38955699
    [No Abstract]   [Full Text] [Related]  

  • 27. Lower Rate of CTNNB1 Mutations and Higher Rate of APC Mutations in Desmoid Fibromatosis of the Breast: A Series of 134 Tumors.
    Norkowski E; Masliah-Planchon J; Le Guellec S; Trassard M; Courrèges JB; Charron-Barra C; Terrier P; Bonvalot S; Coindre JM; Laé M
    Am J Surg Pathol; 2020 Sep; 44(9):1266-1273. PubMed ID: 32590455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 'Difficult to diagnose' desmoid tumours: a potential role for CTNNB1 mutational analysis.
    Colombo C; Bolshakov S; Hajibashi S; Lopez-Terrada L; Wang WL; Rao P; Benjamin RS; Lazar AJ; Lev D
    Histopathology; 2011 Aug; 59(2):336-40. PubMed ID: 21884214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of
    Mir O; Honoré C; Chamseddine AN; Dômont J; Dumont SN; Cavalcanti A; Faron M; Rimareix F; Haddag-Miliani L; Le Péchoux C; Levy A; Court C; Briand S; Fadel E; Mercier O; Bayle A; Brunet A; Ngo C; Rouleau E; Adam J; Le Cesne A
    Clin Cancer Res; 2020 Dec; 26(23):6277-6283. PubMed ID: 32873570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors for the recurrence of sporadic desmoid-type fibromatosis after macroscopically complete resection: Analysis of 114 patients at a single institution.
    He XD; Zhang YB; Wang L; Tian ML; Liu W; Qu Q; Li BL; Hong T; Li NC; Na YQ
    Eur J Surg Oncol; 2015 Aug; 41(8):1013-9. PubMed ID: 26005133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution.
    Huang K; Fu H; Shi YQ; Zhou Y; Du CY
    J Surg Oncol; 2009 Dec; 100(7):563-9. PubMed ID: 19722232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is immunohistochemical staining for β-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional study.
    Koike H; Nishida Y; Kohno K; Shimoyama Y; Motoi T; Hamada S; Kawai A; Ogose A; Ozaki T; Kunisada T; Matsumoto Y; Matsunobu T; Ae K; Gokita T; Sakai T; Shimizu K; Ishiguro N
    Hum Pathol; 2019 Feb; 84():155-163. PubMed ID: 30292627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors.
    Salas S; Chibon F; Noguchi T; Terrier P; Ranchere-Vince D; Lagarde P; Benard J; Forget S; Blanchard C; Dômont J; Bonvalot S; Guillou L; Leroux A; Mechine-Neuville A; Schöffski P; Laë M; Collin F; Verola O; Carbonnelle A; Vescovo L; Bui B; Brouste V; Sobol H; Aurias A; Coindre JM
    Genes Chromosomes Cancer; 2010 Jun; 49(6):560-8. PubMed ID: 20232483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention.
    van Broekhoven DL; Grünhagenl DJ; van Dalen T; van Coevorden F; Bonenkamp HJ; Been LB; Bemelmans MH; Dijkstra SD; Colombo C; Gronchi A; Verhoef C
    BMC Cancer; 2016 Aug; 16(1):686. PubMed ID: 27565718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool.
    Amary MF; Pauwels P; Meulemans E; Roemen GM; Islam L; Idowu B; Bousdras K; Diss TC; O'Donnell P; Flanagan AM
    Am J Surg Pathol; 2007 Sep; 31(9):1299-309. PubMed ID: 17721184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resection of adrenocortical carcinoma liver metastasis: is it justified?
    Gaujoux S; Al-Ahmadie H; Allen PJ; Gonen M; Shia J; D'Angelica M; Dematteo R; Fong Y; Blumgart L; Jarnagin WR
    Ann Surg Oncol; 2012 Aug; 19(8):2643-51. PubMed ID: 22526905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Droplet Digital PCR (ddPCR) as a Novel Technology in Detecting CTNNB1 Mutations in Desmoid Fibromatosis.
    Gandhi J; Kao E; Wu Y; Mantilla JG; Ricciotti RW; Bandhlish A; Liu YJ; Chen EY
    Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):662-667. PubMed ID: 36227098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis.
    Colombo C; Fiore M; Grignani G; Tolomeo F; Merlini A; Palassini E; Collini P; Stacchiotti S; Casali PG; Perrone F; Mariani L; Gronchi A
    Clin Cancer Res; 2022 Sep; 28(18):4027-4032. PubMed ID: 35247923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CORR Insights®: Does the Addition of Mutations of CTNNB1 S45F to Clinical Factors Allow Prediction of Local Recurrence in Patients With a Desmoid Tumor? A Local Recurrence Risk Model.
    Ramsey DC
    Clin Orthop Relat Res; 2023 Oct; 481(10):1990-1992. PubMed ID: 37159234
    [No Abstract]   [Full Text] [Related]  

  • 40. WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor.
    Cardoso LC; De Souza KR; De O Reis AH; Andrade RC; Britto AC; De Lima MA; Dos Santos AC; De Faria PS; Ferman S; Seuánez HN; Vargas FR
    Oncol Rep; 2013 Jan; 29(1):315-20. PubMed ID: 23117548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.